Biogen Idec Inc (BIIB): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Biogen Idec ( BIIB) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.6%. By the end of trading, Biogen Idec rose $3.05 (1.5%) to $210.80 on average volume. Throughout the day, 1,414,034 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,473,000 shares. The stock ranged in a price between $206.43-$211.62 after having opened the day at $210.47 as compared to the previous trading day's close of $207.75. Other companies within the Drugs industry that increased today were: Cytokinetics ( CYTK), up 29.4%, Prothena Corporation ( PRTA), up 16.0%, Infinity Pharmaceuticals ( INFI), up 13.3% and TG Therapeutics ( TGTX), up 11.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $50.3 billion and is part of the health care sector. The company has a P/E ratio of 33.6, above the S&P 500 P/E ratio of 17.7. Shares are up 44.8% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Biota Pharmaceuticals ( BOTA), down 68.0%, MannKind Corporation ( MNKD), down 12.4%, Opexa Therapeutics ( OPXA), down 11.3% and Oramed Pharmaceuticals ( ORMP), down 7.9% , were all laggards within the drugs industry with Onyx Pharmaceuticals ( ONXX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire